JWCA advises ULTRAGENYX on its $320 million FINANCING OF FUTURE CRYSVITA EU ROYALTIES

DECEMBER 2019 | read press release

Transaction Background

Ultragenyx Pharmaceutical, Inc. (“the Company”) hired J. Wood Capital Advisors as its Financial Advisor to advise on a capital raise based on the Company’s rights to receive royalties from net sales of Crysvita in the EU and Switzerland

Objectives:

• Pull forward value and proceeds from a passive royalty stream to drive the Company’s strategic plan

• Maximize proceeds to continue supporting the launches of Crysvita in North and Latin America and Mespevii worldwide, as well as future pipeline

• Maintain upside in Crysvita’s European royalty stream

• Achieve cost of capital lower than other financing options available

• Provide flexibility for future financing

JWCA designed and ran a competitive process that could best help Ultragenyx achieve its objectives.  Upon obtaining terms from lenders, JWCA:

• Analyzed different structures to help the Company select the proposal that best met its objectives

• Negotiated with lenders on Company’s behalf to obtain the best terms available

Results

• Helped the Company to raise capital in a challenging macro environment without adding debt or dilution

• Achieved financing outcome that balanced the Company’s objectives, including proceeds raised, maintaining upside in Crysvita’s European sales, and low cost of capital